ATRA
Price
$0.65
Change
-$0.01 (-1.52%)
Updated
Dec 1, 6:59 PM EST
86 days until earnings call
EDIT
Price
$10.77
Change
+$0.24 (+2.28%)
Updated
Dec 1, 6:59 PM EST
81 days until earnings call
Ad is loading...

ATRA vs EDIT ᐉ Comparison: Which is Better to Invest?

Header iconATRA vs EDIT Comparison
Open Charts ATRA vs EDITBanner chart's image
Atara Biotherapeutics
Price$0.65
Change-$0.01 (-1.52%)
Volume$1.41M
CapitalizationN/A
Editas Medicine
Price$10.77
Change+$0.24 (+2.28%)
Volume$964.43K
CapitalizationN/A
View a ticker or compare two or three
ATRA vs EDIT Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ATRA vs. EDIT commentary
Dec 03, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a StrongBuy and EDIT is a Buy.

COMPARISON
Comparison
Dec 03, 2023
Stock price -- (ATRA: $0.65 vs. EDIT: $10.77)
Brand notoriety: ATRA and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 50% vs. EDIT: 95%
Market capitalization -- ATRA: $64.28M vs. EDIT: $870.23M
ATRA [@Biotechnology] is valued at $64.28M. EDIT’s [@Biotechnology] market capitalization is $870.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than ATRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 6 bullish TA indicator(s).

  • ATRA’s TA Score: 5 bullish, 3 bearish.
  • EDIT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both ATRA and EDIT are a good buy in the short-term.

Price Growth

ATRA (@Biotechnology) experienced а -0.60% price change this week, while EDIT (@Biotechnology) price change was +1.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +30.64%, and the average quarterly price growth was +27.15%.

Reported Earning Dates

ATRA is expected to report earnings on Feb 27, 2024.

EDIT is expected to report earnings on Feb 22, 2024.

Industries' Descriptions

@Biotechnology (+3.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ATRA with price predictions.
OPEN
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EDIT($870M) has a higher market cap than ATRA($64.3M). EDIT YTD gains are higher at: 21.421 vs. ATRA (-80.250). EDIT has higher annual earnings (EBITDA): -202.49M vs. ATRA (-333.73M). EDIT has more cash in the bank: 350M vs. ATRA (102M). EDIT has less debt than ATRA: EDIT (34.6M) vs ATRA (61.8M). EDIT has higher revenues than ATRA: EDIT (24.6M) vs ATRA (4.54M).
ATRAEDITATRA / EDIT
Capitalization64.3M870M7%
EBITDA-333.73M-202.49M165%
Gain YTD-80.25021.421-375%
P/E RatioN/AN/A-
Revenue4.54M24.6M18%
Total Cash102M350M29%
Total Debt61.8M34.6M179%
FUNDAMENTALS RATINGS
ATRA vs EDIT: Fundamental Ratings
ATRA
EDIT
OUTLOOK RATING
1..100
1650
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
9736
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (45) in the Biotechnology industry is in the same range as ATRA (77). This means that EDIT’s stock grew similarly to ATRA’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that EDIT’s stock grew similarly to ATRA’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as ATRA (100). This means that EDIT’s stock grew similarly to ATRA’s over the last 12 months.

EDIT's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for ATRA (97). This means that EDIT’s stock grew somewhat faster than ATRA’s over the last 12 months.

EDIT's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that EDIT’s stock grew similarly to ATRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRAEDIT
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 6 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MAIFF0.270.01
+2.92%
Minera Alamos
RTMVY14.110.32
+2.32%
Rightmove Plc
SNMRY10.110.09
+0.95%
Snam SpA
RBGLY13.700.08
+0.59%
Reckitt Benckiser Plc
VOCL0.01N/A
-7.20%
Creatd